Sofinnova Partners

www.sofinnovapartners.com

Sofinnova Partners focuses on breakthrough innovations in biopharma, medtech, digital medicine, agriculture, and industrial biotech that contribute to people's health and well-being. They are active across the entire life sciences value chain from seed to later-stage investments, with particular emphasis on companies that have the potential to become market leaders.

Check Size

Not specified

Stages

Seed, Series A, Series B, Growth

Focus Areas

Biotech, Medtech, Digital Health

Is Sofinnova Partners right for your startup?

Upload your pitch deck and get an AI-powered match score in minutes. See exactly how well you fit their investment criteria.

See If You're a Match

Investment Thesis

Sofinnova Partners believes in investing in breakthrough innovations that solve the world’s most pressing problems. Their core philosophy centers on the conviction that treating patients and saving lives creates positive investor returns: ‘If you treat patients, you save lives, ultimately this is going to be good for investors. We believe that by backing companies, whether early stage or later stage, that bring a product to patients — ultimately this translates into financial return.’ They emphasize that sustainable growth can be achieved in parallel with attractive financial returns, viewing ethical business practices and environmental stewardship as compatible with strong financial performance.

What Sets Them Apart

Known for being 'company creators' - they launch early-stage companies through dedicated accelerators (MD Start and Biovelocita)
Multi-fund platform with 7 specialized investment strategies and dedicated teams for different stages and sectors
50+ years of experience (founded 1972) having backed 500+ companies and created numerous market leaders globally
Over €4 billion in assets under management providing significant resources and network
'Partners for Life' cornerstone - building lasting relationships with trust and transparency
Hands-on, operational approach to company building rather than passive investment
Strong European presence and leadership, particularly in industrial biotech sustainability solutions